2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

(2015)   Oncotarget

Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells

(2014) Quang-Dé Nguyen et al.   Translational Oncology

Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F-FDG uptake in vivo in the human glioma xenograft model U87-MG

(2012) H. Keen et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis

(2011) Patsuree Cheebsumon et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical dynamic18F-FDG PET – tumor characterization and radiotherapy response assessment by kinetic compartment analysis

(2010) Kathrine Røe et al.   ACTA ONCOLOGICA

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas

(2009) M. R. Benz et al.   CLINICAL CANCER RESEARCH

[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

(2009) Wen Wee Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET

(2009) K. B. Contractor et al.   JOURNAL OF NUCLEAR MEDICINE

Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non-Small Cell Lung Cancer with the mTOR Inhibitor Everolimus

(2009) L. Nogova et al.   JOURNAL OF NUCLEAR MEDICINE

Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards

(2009) Q. Bao et al.   JOURNAL OF NUCLEAR MEDICINE

Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review

(2009) L.-F. de Geus-Oei et al.   JOURNAL OF NUCLEAR MEDICINE

Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma

(2008) L. H. Wei et al.   CLINICAL CANCER RESEARCH

Tumor Cell Metabolism Imaging

(2008) C. Plathow et al.   JOURNAL OF NUCLEAR MEDICINE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Targeting phosphoinositide 3-kinase—Moving towards therapy

(2007) Romina Marone et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

(2007) Noriaki Sunaga et al.   LUNG CANCER